BCR-ABL Inhibitor ELVN-001

Preferred Label : BCR-ABL Inhibitor ELVN-001;

NCIt synonyms : BCR-ABL Tyrosine Kinase Inhibitor ELVN-001; BCR-ABL TKI ELVN-001;

NCIt definition : An orally bioavailable, selective, active-form inhibitor of tyrosine kinase BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, BCR-ABL inhibitor ELVN-001 specifically targets and binds to the ATP-binding site in the kinase domain of activated BCR-ABL1, thereby inhibiting the activity of both wild-type BCR-ABL and certain mutation forms, including the T315I mutation. This binding results in the inhibition of BCR-ABL-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph ) hematological malignancies. The BCR-ABL fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome. The T315I mutation, the most common BCR-ABL mutation, shows resistance to nearly all commonly used tyrosine kinase inhibitors (TKIs).;

Molecule name : ELVN-001; ELVN 001;

NCI Metathesaurus CUI : CL1799383;

Details

Origin ID

C190745;

UMLS CUI

C5783900;

Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Receptor Tyrosine Kinase Inhibition [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Inhibition of Cell Proliferation [NCIt concept]
- Signal Transduction Inhibition [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- BCR/ABL1 Fusion Protein [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients